Table 1 Characteristics of the enrolled patients (n = 101)
Baseline Characteristics | Chemotherapy | Preoperative | Surgical Outcomes | ||||
|---|---|---|---|---|---|---|---|
Age, median, years | 52 (range 26–78) | Regimen | BMI | Peritoneal infiltration | |||
Gender | Platinum + FU | 51 (50.5) | Normal | 39 (38.6) | No | 69 (68.3) | |
Male | 60 (59.4) | Taxane + FU | 12 (11.9) | Under weight | 9 (8.9) | Yes | 32 (31.7) |
Female | 41 (40.6) | Platinum + Taxane + FU | 15 (14.9) | Over weight | 53 (52.5) | Metastasectomy | |
cT stage | Taxane + Platinum | 16 (15.8) | Change of CEA level | No | 90 (89.1) | ||
Serosa negative | 20 (19.8) | Others | 7 (6.9) | Stable | 66 (65.3) | Yes | 11 (10.9) |
Serosa positive | 81 (80.2) | Best response | Improved | 16 (15.8) | Hepatectomy | 3 | |
cN stage | Overall | Worse | 3 (3.0) | #16 | 6 | ||
N0/N1 | 16 (15.8) | CR/PR | 65 (64.4) | NA | 16 (15.8) | Oophorectomy | 3 |
N2/N3 | 85 (84.2) | SD/PD | 36 (35.6) | Change of CA19–9 level | Extent of gastrectomy | ||
Type of distant metastasis | Local region | Stable | 66 (65.3) | TG | 57 (56.4) | ||
Peritoneal carcinomatosis | 33 (32.7) | CR/PR | 47 (46.5) | Improved | 10 (9.9) | DG | 44 (43.6) |
Liver metastasis | 11 (10.9) | SD/PD | 54 (53.5) | Worse | 5 (5.0) | Extent of LND | |
Distant LN metastasis | 35 (34.7) | Metastatic site | NA | 20 (19.8) | < D2 | 25 (24.8) | |
Krukenberg tumor | 2 (2.0) | CR/PR | 84 (83.2) | Pre_op cT stage | ≥ D2 | 76 (75.2) | |
Any combination | 20 (19.8) | SD/PD | 17 (16.8) | Serosa negative | 48 (47.5) | Complete macroscopic resection | |
NLR (Neut/lympho) | 2.67 ± 1.30 | Preoperative response | Serosa positive | 53 (52.5) | Yes | 57 (56.4) | |
SII (PLT*Neut/lympho) | 9.14 ± 6.88 | Overall | Pre_op cN stage | No | 44 (43.6) | ||
Albumin (g/dL) | 3.94 ± 0.53 | CR/PR | 60 (59.4) | N0/N1 | 33 (32.7) | pT stage | |
SD/PD | 41 (40.6) | N2/N3 | 68 (67.3) | Serosa negative (pT1–3) | 47 (46.5) | ||
Local region | Interval to surgery | Serosa positive (pT4a/b) | 54 (53.5) | ||||
CR/PR | 43 (42.6) | ≤ 24 weeks | 51 (50.5) | pN stage | |||
SD/PD | 58 (57.4) | > 24 weeks | 50 (49.5) | pN0/N1 | 35 (34.7) | ||
Metastatic site | pN2/N3 | 66 (65.3) | |||||
CR/PR | 78 (77.2) | Lauren classification | |||||
SD/PD | 23 (22.8) | Intestinal | 46 (45.5) | ||||
Number of Cycles of Chemotherapy | 6 (range 1–32) | Diffuse | 42 (41.6) | ||||
≤ 6 cycles | 62 (61.4) | Others | 13 (12.9) | ||||
> 6 cycles | 39 (38.6) | Postoperative chemotherapy | |||||
No | 17 (16.8) | ||||||
Yes | 84 (83.2) | ||||||